Necitumumab

A mechanistic class effect of EGFR blockade. EGF, processed and basolaterally secreted by the distal convoluted tubule, is a magnesiotropic hormone that activates the apical TRPM6 magnesium channel; blocking the EGFR with necitumumab removes this stimulus, reducing TRPM6-mediated active magnesium reabsorption in the distal convoluted tubule and producing renal magnesium wasting (inappropriately high fractional excretion of magnesium) and hypomagnesemia. Resultant intracellular magnesium depletion impairs PTH secretion/action and renal potassium handling, generating secondary hypocalcemia and hypokalemia.

Low serum magnesium, sometimes profound and symptomatic (weakness, neuromuscular irritability/tetany, prolonged QT and arrhythmia risk), with inappropriately high 24-hour urinary magnesium or fractional excretion of magnesium >2-4% despite hypomagnesemia; frequently accompanied by refractory hypocalcemia and hypokalemia. Frank AKI is not the characteristic injury.

Develops cumulatively over weeks of repeated dosing and worsens with continued therapy; magnesium should be checked before each dose and for at least 8 weeks after completion because deficits persist.

Recombinant human IgG1 monoclonal antibody against the epidermal growth factor receptor (EGFR), blocking ligand binding and downstream RAS/MAPK and PI3K/AKT proliferative signaling. Approved with gemcitabine and cisplatin for first-line metastatic squamous non-small cell lung cancer.

Replace magnesium—oral magnesium salts for mild deficits, intravenous magnesium sulfate for severe (<1.0 mg/dL) or symptomatic ones—and correct accompanying hypocalcemia and hypokalemia (which are often refractory until magnesium is restored). Hold dosing for severe hypomagnesemia until corrected, and continue monitoring after treatment because the channel defect and deficits can persist for weeks.